Go Pro
→ Gold Miners Post Record Cash Flow Even as Prices Pull Back (From Golden Portfolio) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$534.40
+1.0%		$529.53
$393.61
▼
$615.00
$12.22B-0.98202,371 shs153,300 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
+1.00%+0.24%+1.91%+5.66%+28.02%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$534.40
+1.0%		$529.53
$393.61
▼
$615.00
$12.22B-0.98202,371 shs153,300 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
+1.00%+0.24%+1.91%+5.66%+28.02%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.78
Moderate Buy$699.6430.92% Upside

Current Analyst Ratings Breakdown

Latest MDGL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/4/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$605.00
8/3/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$964.00 ➝ $962.00
7/31/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/31/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/31/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$964.00 ➝ $962.00
7/29/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$578.00 ➝ $587.00
7/27/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$685.00
7/27/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$685.00
7/17/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/17/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 9/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$958.40M12.88N/AN/A$26.54 per share20.14
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$288.28M-$12.89N/A96.29N/A-25.32%-56.65%-25.53%11/3/2026 (Estimated)

Latest MDGL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2026Q2 2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$2.68-$1.99+$0.69-$1.99$352.13 million$364.25 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.65
3.20
2.94

Institutional Ownership

CompanyInstitutional Ownership
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%

Insider Ownership

CompanyInsider Ownership
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
17.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
91523.10 million19.04 millionOptionable

Recent News About These Companies

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - September 16, 2026
September 17 at 8:44 AM  |  biospace.comB
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
September 16 at 4:05 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/16/3363532/0/en/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4.html
Insider Selling: Madrigal Pharmaceuticals (NASDAQ:MDGL) CEO Sells 5,221 Shares of Stock
September 12, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-mdgl-insider-buying-and-selling-2026-09-12/
Madrigal Pharmaceuticals (NASDAQ:MDGL) CEO William John Sibold Sells 5,221 Shares
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-madrigal-pharmaceuticals-nasdaq-mdgl-ceo-william-john-sibold-sells-5221-shares-2026-09-11/
William John Sibold Sells 6,362 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-william-john-sibold-sells-6362-shares-of-madrigal-pharmaceuticals-nasdaq-mdgl-stock-2026-09-11/
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
September 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4945194-madrigal-pharmaceuticals-inc-mdgl-presents-at-12th-annual-cantor-fitzgerald-global-healthcare
Hsbc Holdings PLC Grows Stake in Madrigal Pharmaceuticals, Inc. $MDGL
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hsbc-holdings-plc-grows-stake-in-madrigal-pharmaceuticals-inc-mdgl-2026-09-10/
Madrigal Pharmaceuticals, Inc. $MDGL Shares Purchased by California State Teachers Retirement System
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-has-496-billion-stock-position-in-madrigal-pharmaceuticals-inc-mdgl-2026-09-10/
Public Employees Retirement System of Ohio Invests $2.74 Million in Madrigal Pharmaceuticals, Inc. $MDGL
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-public-employees-retirement-system-of-ohio-invests-274-million-in-madrigal-pharmaceuticals-inc-mdgl-2026-09-06/
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ubs-am-a-distinct-business-unit-of-ubs-asset-management-americas-llc-increases-stock-holdings-in-madrigal-pharmaceuticals-inc-mdgl-2026-09-05/
Legal & General Group Plc Invests $6.63 Million in Madrigal Pharmaceuticals, Inc. $MDGL
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-legal-general-group-plc-invests-663-million-in-madrigal-pharmaceuticals-inc-mdgl-2026-09-03/
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference
September 2, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/madrigal-pharmaceuticals-to-participate-in-the-2026-cantor-global-healthcare-conference-1036515145
Madrigal Pharmaceuticals to Participate in the  2026 Cantor Global Healthcare Conference
September 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3355104/0/en/madrigal-pharmaceuticals-to-participate-in-the-2026-cantor-global-healthcare-conference.html
Two Sigma Securities LLC Makes New Investment in Madrigal Pharmaceuticals, Inc. $MDGL
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-two-sigma-securities-llc-makes-new-investment-in-madrigal-pharmaceuticals-inc-mdgl-2026-09-01/
The Manufacturers Life Insurance Company Invests $6.55 Million in Madrigal Pharmaceuticals, Inc. $MDGL
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-the-manufacturers-life-insurance-company-invests-655-million-in-madrigal-pharmaceuticals-inc-mdgl-2026-08-31/
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Rating of "Moderate Buy" by Analysts
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-madrigal-pharmaceuticals-inc-nasdaq-mdgl-given-consensus-rating-of-moderate-buy-by-analysts-2026-08-31/
Madrigal Pharmaceuticals, Inc. $MDGL Shares Bought by Wellington Management Group LLP
August 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-madrigal-pharmaceuticals-inc-mdgl-shares-bought-by-wellington-management-group-llp-2026-08-30/
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by Algert Global LLC
August 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-madrigal-pharmaceuticals-inc-mdgl-shares-sold-by-algert-global-llc-2026-08-30/
Hsbc Holdings PLC Makes New Investment in Madrigal Pharmaceuticals, Inc. $MDGL
August 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hsbc-holdings-plc-makes-new-investment-in-madrigal-pharmaceuticals-inc-mdgl-2026-08-29/
Canada Pension Plan Investment Board Takes Position in Madrigal Pharmaceuticals, Inc. $MDGL
August 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-canada-pension-plan-investment-board-takes-position-in-madrigal-pharmaceuticals-inc-mdgl-2026-08-29/
Bamco Inc. NY Makes New $2.42 Million Investment in Madrigal Pharmaceuticals, Inc. $MDGL
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bamco-inc-ny-makes-new-242-million-investment-in-madrigal-pharmaceuticals-inc-mdgl-2026-08-28/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$534.40 +5.31 (+1.00%)
Closing price 09/17/2026 04:00 PM Eastern
Extended Trading
$532.50 -1.90 (-0.36%)
As of 09/17/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas